joining today's Jenna, on and and morning, us call. thanks for good everyone, Thanks,
expectations. this news first for But Briumvi. of representing which, are excited our financial quarter I our do, want XXXX first like before off the quarter to of today's the to ex-U.S. you morning's present sales, second relating quarter by exceeded to of full kick highlighting to results, our commercialization XXXX We I Briumvi call agreement
recall, very happy was Briumvi CNS agreement European adult clinical ex-U.S. on defined Today, forms who you approved of of entered European have specialty As Neuraxpharm, Briumvi company or leading that system disorders. disorders announce in Union June, to or focused disease active we've we into commercialization MS to relapsing with an a imaging for central by may the patients the pharmaceutical are features. treat with treatment in nervous
be The We partnering are resonated broad with excited in with platform and Briumvi launch to as TG. entrepreneurial to for them attractive Europe. really European Briumvi an very and us partner neurology-focused organization approach,
years countries extensive over presence CNS private of addition, field-based global XXX experience of And firm an backing they Permira. commercial additional and of the in have they a XX team. Neuraxpharm XX and in MS CNS equity the has space, to Briumvi. one direct European have specialists to dedicated preeminent in Moreover, the committed is commercial over medical add
patients in treatment worldwide. confident and to are their leading For make we all of ability Briumvi with these a for reasons, succeed RMS
payments certain $XXX receive payment, $XXX total From million, evaluating of up deal near-term million. a when including the to an potential seeking to ex-U.S. based us terms in we that achievement a with launch meaningful were a $XXX total over deal many milestone, important for perspective, benefits sheet. approximately balance the upfront our partnerships We're together milestone provide value to and solidifying which a commercial objectives on additional at million also eligible with
world. we think participation of we the Europe up And XX%, royalties Briumvi which net on of in the sales, to the rest in double-digit We will also receive significant and lastly success provide and tiered product under deal, with strategic commercialization all the of rights as event retained option back agreement. X TG an next in importantly, years buy an part the the within to flexibility of acquisition the of very
As will the core countries, need. considering the our type have Asian territories Neuraxpharm excluding partnered. we right backers ex-U.S. In and transaction their appreciated States, and which previously, that strategic of to retained which exchange, previously in commercialize in we have an noted flexibility retaining was to Briumvi Canada had this Neuraxpharm and exclusive we United certain outside Mexico,
they believe which to which we remains earlier, launch positioned touch focus. let As upon Briumvi U.S. that, our primary successfully excited in the to I with next Neuraxpharm to we X expect commence Briumvi said partner are are With very months. Germany me the in and Europe, well efforts, in launch
year officially a of MS that dose. approval following can January and launched FDA of relapsing first at year and as anti-CDXX late to with U.S. monoclonal of As reminder, the treat starting twice administered antibody forms infusion per end Briumvi this a only the year patients X-hour last in the received be
for Briumvi experienced noteworthy over illustrating that Equally and this new embrace the to breadth to strong willing first I'm trust and the year, they we we providers the this early centers growth share confidence and is is demonstrating of believe demand Briumvi. significant quarter revenues TG. delighted prescriptions in and have treatment what in option, of
enthusiasm MS Briumvi monoclonal dedication and team potential, attributes are B-cell us to trials Briumvi antibody III RMS. X-hour bring testament infusion. rates reliable passion Our of including received who to relapse lowest our encourage the that depletion, glycoengineering the best-in-class with supportive its in continues a and any reported Briumvi annualized early efficient for to rapid and TG its Phase of of patients a unique and of CDXX have feedback to performance The build for relentlessly have to we continues is worked entire the
a the Briumvi move into we believe we As future for third we are building quarter, growth. solid foundation
improving from adoption that and insurance and place Briumvi. major centers grow, continue that permanent academic that, both for a J-Code We coverage continue we see to and especially centers to in adoption believe will community now have
market treatment landscape, overall MS within the our with further All factors, the confidence of growth of Briumvi. strengthen potential the along future these the in continuing of CDXX
provide I'll I'm stop Waldman as progress there detailed as shortly with date to forward extremely metrics. made Officer, team impressed us hear, and second more to impactful launch of half join to Commercialization can XXXX. But our the look the Chief Adam you an has will
call the Adam, over turn briefly want I I just position. Before to cash to TG's touch on
Following pro we million. forma $XXX have the balance Neuraxpharm transaction, of approximately cash
capital have without Given operations we foreseeable revenues, our fund relatively our sufficient the capital. need believe growing stable future to the raise we OpEx additional and now into to
as projection our with are we subject Of to variables, of is cash this but today, to confident say, suffice course, many position.
Officer, Adam on color Chief quarter the some Commercialization Adam? call first additional Waldman, our to to share With that, let turn me our full launch. over of
